These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 32176102

  • 1. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y, Ishibashi E, Honda S, Nakaya T, Noguchi C, Kagawa K, Murakami K.
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [Abstract] [Full Text] [Related]

  • 2. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM, Lesmana E, Fass R.
    J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T, Iwakiri K.
    Digestion; 2017 May; 95(2):156-161. PubMed ID: 28190016
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J, Hosaka H, Kuribayashi S, Moriyasu S, Hisada Y, Okubo H, Watanabe K, Imbe K, Nagata N, Kojima Y, Yokoi C, Uemura N, Shimoyama Y, Kawamura O, Yamada M, Kusano M.
    Digestion; 2020 May; 101(2):174-183. PubMed ID: 30897577
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis.
    Mizuno H, Nishino M, Yamada K, Kamiyamamoto S, Hinoue Y.
    Digestion; 2020 May; 101(4):411-421. PubMed ID: 31129668
    [Abstract] [Full Text] [Related]

  • 6. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
    Abe Y, Koike T, Saito M, Okata T, Nakagawa K, Hatta W, Asanuma K, Uno K, Asano N, Imatani A, Masamune A.
    Digestion; 2021 May; 102(3):480-488. PubMed ID: 32062650
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
    Niikura R, Yamada A, Hirata Y, Hayakawa Y, Takahashi A, Shinozaki T, Takeuchi Y, Fujishiro M, Koike K.
    Intern Med; 2018 Sep 01; 57(17):2443-2450. PubMed ID: 29607951
    [Abstract] [Full Text] [Related]

  • 8. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S, Osawa H, Kobayashi Y, Sakamoto H, Hayashi Y, Miura Y, Kawarai Lefor A, Yamamoto H.
    Scand J Gastroenterol; 2018 Aug 01; 53(8):897-904. PubMed ID: 30056768
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
    Miyamoto M, Manabe N, Haruma K.
    Intern Med; 2010 Aug 01; 49(15):1469-76. PubMed ID: 20686276
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M, Nakahara K, Iwakura N, Hasegawa T, Oyama M, Inoue A, Ishizu H, Satoh H, Fujiwara Y.
    Digestion; 2017 Aug 01; 95(4):281-287. PubMed ID: 28501868
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The presence of hiatal hernia is a significant predictor for symptomatic recurrence after cessation of vonoprazan therapy for gastroesophageal reflux disease: a long-term observational study.
    Shinozaki S, Osawa H, Miura Y, Sakamoto H, Hayashi Y, Yano T, Despott EJ, Yamamoto H.
    Scand J Gastroenterol; 2024 Aug 01; 59(8):893-899. PubMed ID: 38821110
    [Abstract] [Full Text] [Related]

  • 17. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
    Kusano M, Hosaka H, Kawamura O, Kawada A, Kuribayashi S, Shimoyama Y, Yasuoka H, Mizuide M, Tomizawa T, Sagawa T, Sato K, Yamada M.
    J Gastroenterol; 2015 Mar 01; 50(3):298-304. PubMed ID: 24919745
    [Abstract] [Full Text] [Related]

  • 18. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H, Igarashi A, Takeuchi T, Teng L, Uda A, Deguchi H, Higuchi K, Tango T.
    J Gastroenterol Hepatol; 2019 Aug 01; 34(8):1316-1328. PubMed ID: 30883868
    [Abstract] [Full Text] [Related]

  • 19. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
    Sakurai K, Suda H, Fujie S, Takeichi T, Okuda A, Murao T, Hasuda K, Hirano M, Ito K, Tsuruta K, Hattori M.
    Dig Dis Sci; 2019 Mar 01; 64(3):815-822. PubMed ID: 30415407
    [Abstract] [Full Text] [Related]

  • 20. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H, Igarashi A, Teng L, Uda A, Deguchi H, Tango T.
    J Gastroenterol; 2019 Aug 01; 54(8):718-729. PubMed ID: 30919071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.